All In Biotech

Drug Trial Radar · NCT01899053

A Safety and Pharmacokinetic Study of TAK-228 in Combination With TAK-117 in Adult Participants With Advanced Nonhematologic Malignancies

A Multicenter, Open-label, Phase 1b Study of MLN0128 (an Oral mTORC1/2 Inhibitor) in Combination With MLN1117 (an Oral PI3Kα Inhibitor) in Adult Patients With Advanced Nonhematologic Malignancies

Last checked: Nov 19, 2026Latest source record: Oct 30, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

101

Actual

Start

Jun 28, 2013

Primary completion

Jan 31, 2017

Study completion Apr 30, 2018

Sponsor

Lead sponsor
Millennium Pharmaceuticals, Inc.Takeda (TAK)
Sponsor type
Industry
First posted
Jul 15, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to evaluate the safety and to determine dose-limiting toxicities (DLTs), maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D), and dosing schedules of oral TAK-228+TAK-117. It also evaluated the single- and multiple-dose plasma pharmacokinetics (PK) of TAK-228+TAK-117 in participants with advanced nonhematologic malignancies.

Conditions

  • Advanced Nonhematologic Malignancies

Interventions

  • TAK-228Drug

    TAK-228 Capsules

  • TAK-117Drug

    TAK-117 Capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Experienced at Least One or More Treatment-Emergent Adverse Event (TEAEs) and Serious Adverse Events (SAEs)Time frame: From Baseline to 30 days after the last dose of study drug (Up to approximately 68 weeks)
  2. Tmax: Time to Reach the Maximum Observed Plasma Concentration After Single-dose and Multiple-dose of TAK-228 in the Dose Escalation CohortTime frame: Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose
  3. Cmax: Maximum Observed Plasma Concentration After Single-dose and Multiple-dose of TAK-228 in the Dose Escalation CohortTime frame: Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose
  4. AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Observed Quantifiable Concentration After Single-dose and Multiple-dose of TAK-228 in the Dose Escalation CohortTime frame: Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose
  5. Terminal Phase Elimination Half-life (T1/2) After Single-dose and Multiple-dose of TAK-228 in the Dose Escalation CohortTime frame: Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose
  6. CL/F: Apparent Clearance After Extravascular Administration, Calculated Using the Observed Value of the Last Quantifiable Concentration After Single-dose and Multiple-dose of TAK-228 in the Dose Escalation CohortTime frame: Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose
  7. RAC: Accumulation Ratio for TAK-228 in the Dose Escalation CohortTime frame: Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose
  8. Peak to Trough Ratio for TAK-228 After Single-dose and Multiple-dose of TAK-228 in the Dose Escalation CohortTime frame: Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose
  9. Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) After Single-dose and Multiple-dose of TAK-117 in the Dose Escalation CohortTime frame: Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose
  10. Cmax: Maximum Observed Plasma Concentration After Single-dose and Multiple-dose of TAK-117 in the Dose Escalation CohortTime frame: Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose
  11. AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Observed Quantifiable Concentration After Single-dose and Multiple-dose of TAK-117 in Dose Escalation CohortTime frame: Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose
  12. Terminal Phase Elimination Half-life (T1/2) After Single-dose and Multiple-dose of TAK-117 in Dose Escalation CohortTime frame: Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose
  13. CL/F: Apparent Clearance After Extravascular Administration, Calculated Using the Observed Value of the Last Quantifiable Concentration After Single-dose and Multiple-dose of TAK-117 in Dose Escalation CohortTime frame: Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose
  14. RAC: Accumulation Ratio for TAK-117 in the Dose Escalation CohortTime frame: Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose
  15. Peak to Trough Ratio After Single-dose and Multiple-dose of TAK-117 in Dose Escalation CohortTime frame: Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose
  16. Tmax: Time to Reach the Maximum Observed Plasma Concentration for TAK-228 in DDI Expansion CohortTime frame: Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 10 predose and at multiple timepoints (up to 24 hours) postdose
  17. Cmax: Maximum Observed Plasma Concentration for TAK-228 in DDI Expansion CohortTime frame: Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 10 predose and at multiple timepoints (up to 24 hours) postdose
  18. AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Observed Quantifiable Concentration for TAK-228 in DDI Expansion CohortTime frame: Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 10 predose and at multiple timepoints (up to 24 hours) postdose
  19. Terminal Phase Elimination Half-life (T1/2) for TAK-228 in DDI Expansion CohortTime frame: Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 10 predose and at multiple timepoints (up to 24 hours) postdose
  20. CL/F: Apparent Clearance After Extravascular Administration, Calculated Using the Observed Value of the Last Quantifiable Concentration for TAK-228 in DDI Expansion CohortTime frame: Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 10 predose and at multiple timepoints (up to 24 hours) postdose
  21. Peak to Trough Ratio for TAK-228 in DDI Expansion CohortTime frame: Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 10 predose and at multiple timepoints (up to 24 hours) postdose
  22. Tmax: Time to Reach the Maximum Observed Plasma Concentration for TAK-117 in DDI Expansion CohortTime frame: Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 17 predose and at multiple timepoints (up to 24 hours) postdose
  23. Cmax: Maximum Observed Plasma Concentration for TAK-117 in DDI Expansion CohortTime frame: Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 17 predose and at multiple timepoints (up to 24 hours) postdose
  24. AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Observed Quantifiable Concentration for TAK-117 in DDI Expansion CohortTime frame: Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 17 predose and at multiple timepoints (up to 24 hours) postdose
  25. Terminal Phase Elimination Half-life (T1/2) for TAK-117 in DDI Expansion CohortTime frame: Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 17 predose and at multiple timepoints (up to 24 hours) postdose
  26. CL/F: Apparent Clearance After Extravascular Administration, Calculated Using the Observed Value of the Last Quantifiable Concentration for TAK-117 in DDI Expansion CohortTime frame: Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 17 predose and at multiple timepoints (up to 24 hours) postdose
  27. Peak to Trough Ratio for TAK-117 in DDI Expansion CohortTime frame: Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 17 predose and at multiple timepoints (up to 24 hours) postdose

Locations

5 sites in 3 countries. Site status is shown where the registry gives one.

  • Site not named

    Boston, Massachusetts

  • Site not named

    Nashville, Tennessee

  • Site not named

    San Antonio, Texas

  • Site not named

    Barcelona, Spain

  • Site not named

    Sutton, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.